Search Results
Your search for 3 matches 15291 pages
Showing 301 - 350Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
ASCO 2025: Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Patients With Gastric Cancers
Results from an international phase III clinical trial found that treating patients with stage II, III, and IVA resectable gastric cancer and gastroesophageal junction (GEJ) cancer with perioperative durvalumab and FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) helped...
ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer
A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...
Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer
Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are at high risk for recurrence, according to data presented at the 2025 ASCO Annual Meeting.1 At a...
ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer
Results from the international phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experience a 50% reduction in disease recurrence or death compared with chemotherapy alone. The findings...
Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in ...
Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer
Results from an international phase III clinical trial show that treatment with sacituzumab govitecan-hziy and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–positive triple-negative breast cancer live longer without disease progression compared with...
Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric/GEJ Cancer in Second-Line Setting
The international phase III DESTINY-Gastric04 clinical trial found that second-line treatment with fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live about 3 months longer. These findings further support the...
Vepdegestrant Improves Progression-Free Survival in Select Patients With ESR1-Mutant Advanced Breast Cancer
Results from VERITAC-2 trial showed that the proteolysis-targeting chimera (PROTAC) vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with an ESR1 mutation. The research will be presented at...
Online Genetic Testing Platform Demonstrates Notable Engagement Among Patients With Young-Onset Colorectal Cancer
Universal germline testing is essential for identifying hereditary cancer risk, especially for patients with young-onset colorectal cancer who were diagnosed before the age of 50. However, the implementation of universal germline testing has been hampered by increasing demand and limited physician...
Castor Oil
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Addition of Radium-223 to Stereotactic Ablative Radiotherapy in Oligometastatic Prostate Cancer
In a phase II trial (RAVENS) reported in the Journal of Clinical Oncology, Wang et al attempted to determine whether the addition of the bone metastasis–targeting agent radium-223 to stereotactic ablative radiotherapy improved progression-free survival as metastasis-directed therapy in patients...
FOLFIRINOX vs Gemcitabine in Nonresectable Locally Advanced Pancreatic Carcinoma
In a French phase III trial (NEOPAN) reported in the Journal of Clinical Oncology, Ducreux et al evaluated whether FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) significantly improved progression-free survival vs gemcitabine in patients with locally advanced pancreatic carcinoma not...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Alcohol May Be Linked to Higher Risk of Pancreatic Cancer
Investigators may have uncovered a modest but potentially significant association between alcohol consumption and the risk of developing pancreatic cancer, according to a recent study published by Naudin et al in PLOS Medicine. Background Pancreatic cancer is the twelfth most common cancer type...
First-Line Nivolumab/Ipilimumab vs Lenvatinib or Sorafenib in Unresectable Hepatocellular Carcinoma
In a phase III trial (CheckMate 9DW) reported in The Lancet, Yau et al evaluated whether first-line nivolumab plus ipilimumab improved overall survival vs investigator's choice of lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Study Details In the open-label trial,...
Enhanced CAR T-Cell Therapy for Lymphoma After Previous Failure on CAR T-Cell Therapy
In a single-center phase I trial reported in The New England Journal of Medicine, Svoboda et al assessed the safety, feasibility, and preliminary efficacy of an enhanced chimeric antigen receptor (CAR) T-cell therapy (huCART19-IL18) in patients with relapsed or refractory lymphoma after previous...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
Dose-Escalated Stereotactic Body Radiotherapy vs Conventional Radiotherapy for Painful Bone Metastases
In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was associated with statistically significant benefit vs conventional, single-fraction, 3D conformal...
Mortality Associated With Risk-Adapted Adjuvant Therapy in Postmenopausal Women With Early Breast Cancer
In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts
In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level1,2 and rescinding Biden Administration orders that emphasized the importance of these efforts to promote equal opportunity across government ...
Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma
The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case reports by Baldeep Wirk, MD, and Jin Lim, MD, PhD, both of Virginia Commonwealth University,...
What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?
Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...
In Case You Missed It: Additional Abstracts of Interest in Cancer Research
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management
Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless of the tumor type, researchers from Memorial Sloan Kettering (MSK) Cancer Center reported at the...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC
Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated, HER2-mutant non–small cell lung cancer (NSCLC), according to data presented by John V. Heymach,...
Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
New findings from the phase III INAVO120 trial showed that adding inavolisib to palbociclib and fulvestrant may help extend survival and delay the time until treatment with chemotherapy in previously treated patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The...
Extensive-Stage SCLC: Lurbinectedin and Atezolizumab
Results from a global phase III clinical trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some patients with extensive-stage small cell lung cancer (SCLC) compared with maintenance therapy with...
Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven
Cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte therapy are transforming outcomes for patients with cancer, particularly in the relapsed or refractory setting. “We’re seeing outstanding response rates in patients with B-cell malignancies...
Addition of Tocilizumab to Nab-Paclitaxel and Gemcitabine in First-Line Treatment of Advanced Pancreatic Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Chen et al attempted to determine whether there is a benefit to adding tocilizumab to nab-paclitaxel and gemcitabine in the first-line treatment of patients with advanced pancreatic cancer. Study Details In the open-label trial, 141...
Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...
Stromal Disruption Associated With Higher Risk of Developing Aggressive Breast Cancer
Investigators from the National Cancer Institute (NCI) identified changes in stromal breast tissue, called stromal disruption, that may help to identify women with a higher risk of developing breast cancer, according to study findings published in the Journal of the National Cancer Institute. Women ...
Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer
In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer. As stated by the investigators:...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the ...
Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy may improve progression-free survival vs second-line alternative endocrine therapy alone. Study Details In the...
Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer
In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...
FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous, non–small cell lung cancer (NSCLC) with high c-Met ...
Case 3: Refractory AML with Complex Karyotype and TP53 Mutation
This is Part 3 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 2: Relapsed/Refractory FLT3-Mutant AML
This is Part 2 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 1: Relapsed KMT2A-Rearranged AML
This is Part 1 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases
In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al found that elective nodal radiotherapy (ENRT) to the pelvis was associated with longer metastasis-free survival vs metastasis-directed therapy (MDT) in patients with pelvic nodal oligorecurrences of prostate cancer....
First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al found that afatinib prolonged progression-free survival vs platinum-based chemotherapy in patients who had treatment-naive nonsquamous non–small cell lung cancer (NSCLC) with...
Combination of Weight Gain, Age at Pregnancy Could Increase Breast Cancer Risk
Investigators have found that the risk of developing breast cancer could be nearly three times higher among women who experience notable weight gain after the age of 20 years and either give birth after age 30 or don’t have children compared with those who give birth before age 30 and whose weight...
